#Germany #Berlin #Isotopia #Isoprotrace® #DSD Pharma

Isotopia Officially Launches Isoprotrace® in Germany

Isotopia, recognized as a leading innovator in the field of radiopharmaceuticals, has announced the successful commercial launch of its product Isoprotrace® in Germany. This strategic initiative is undertaken in partnership with DSD Pharma, a reputable pharmaceutical distributor in the region.

A Partnership for Success

DSD Pharma has been appointed as the exclusive distributor for Isoprotrace®, responsible for ensuring that this advanced imaging solution reaches hospitals, clinics, and diagnostic centers across Germany effectively. The collaboration aims to strengthen the medical equipment supply chain, enhancing timely access to crucial healthcare solutions.

What is Isoprotrace®?

Isoprotrace® is an advanced radiopharmaceutical specifically designed for imaging prostate cancer, offering healthcare professionals a reliable tool for assessing patient conditions more accurately. The multi-dose kit enables quick preparation of Gallium (68Ga) Gozetotide solution for intravenous injection, following its radiolabeling with gallium (68Ga) chloride solution. This product is primarily indicated for positron emission tomography (PET) to target prostate-specific membrane antigen (PSMA)-positive lesions in men diagnosed with prostate cancer.

Clinical Applications

The product’s applications are critical in several clinical scenarios:
1. Primary Staging: It assists in the initial assessment of patients with high-risk prostate cancer prior to initiating curative therapy.
2. Cancer Recurrence Confirmation: Isoprotrace® is beneficial when there are suspected prostate cancer recurrences indicated by elevated levels of prostate-specific antigen (PSA) following prior treatments.

Prostate Cancer in Germany

In Germany alone, prostate cancer is alarmingly prevalent, with over 70,000 new diagnoses reported annually. The importance of accurate imaging for disease diagnosis and treatment planning cannot be overstated. Through the launch of Isoprotrace®, Isotopia emphasizes its commitment to providing healthcare solutions that significantly contribute toward improving patient outcomes.

Commitment to Market Success

The general manager of Isotopia’s aseptic plant, Tzachi Levy, expressed enthusiasm about the collaboration, stating, “Germany is a key market for Isoprotrace®, and we are confident that this collaboration will ensure the successful introduction and accessibility of this innovative product to healthcare providers across the country.”

DSD Pharma’s Managing Director, Dr. Susanne Dorudi, echoed this sentiment, highlighting that their partnership with Isotopia would provide German medical professionals with a groundbreaking imaging solution. The potential impact of introducing Isoprotrace® into the market reflects both companies' dedication to providing cutting-edge healthcare advancements.

Looking Ahead

Isoprotrace® is not only set to make waves in Germany; it has also already received approval in the Netherlands, with plans in motion to make it available in more than ten EU countries soon. Isotopia prides itself on a robust supply chain and a strong compliance record, reinforcing its commitment to patient-centered care through rapid and safe distribution of Isoprotrace®.

About Isotopia and DSD Pharma

Isotopia has consistently led the way in developing innovative radiopharmaceuticals aimed at enhancing medical imaging and therapy. DSD Pharma boasts an extensive distribution network across Austria, Germany, and Switzerland, focusing on bringing innovative healthcare solutions to market while collaborating with leading global partners.

This collaborative endeavor illustrates Isotopia’s and DSD Pharma's commitment to revolutionizing how healthcare is delivered, demonstrating the continuous evolution of medical technology in the battle against cancer.